BENLYSTA

GlaxoSmithKline Inc🇨🇦 Health Canada

Approval Id: 55370a7e9279082c
Drug Approval Canada Name: BENLYSTA
Product Name: BENLYSTA
Status: Marketed
Status Date: 2018-05-14
Original Market Date: 2018-05-14
Din: 02470489
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Prescription , Schedule D
Ahfs: 90:24.28
Atc Original: L04AG04 BELIMUMAB
Atc Name: l 04 ag 04
Aig Number: 0152941003
Company Name: GlaxoSmithKline Inc
Company Address: 800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path: /organization/glaxosmithkline-inc

BELIMUMAB

200 MG / 1 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

55370a7e9279082c

Type

Standard